Protect Infant Formula from Contamination Act

1) What happened and its current status: The 'Protect Infant Formula from Contamination Act' (S.272) was passed by the Senate on 2026-04-28 via unanimous consent. It is now awaiting action in the House of Representatives. The bill was introduced by Sen. Peters (D-MI) in the 119th Congress and has 9 cosponsors. It was reported favorably by the HELP Committee on 2026-01-28. The legislative velocity through the Senate has been brisk, indicating strong bipartisan support for food safety measures following the 2022 infant formula crisis. 2) The money trail: This bill authorizes zero new appropriations. It imposes unfunded mandates on infant formula manufacturers. Compliance costs include: building or upgrading laboratory testing capabilities to meet the 1-business-day notification requirement for positive microbiological results, implementing systems to track contamination knowledge within tight timelines, potential costs from FDA-mandated product isolation and disposal, and legal costs from increased FDA oversight. The Congressional Budget Office would typically score this as having no direct federal spending, but manufacturers bear the cost. 3) Structural winners and losers: The primary loser is AbbVie ($ABBV), which through historical acquisitions holds Abbott's former nutrition division. The company's Similac brand is the market leader in US infant formula. The new compliance regime adds fixed cost to every production batch. Smaller players like Perrigo ($PRGO), which manufactures store-brand infant formula, face proportionally higher compliance costs relative to revenue, though large players like $ABBV also face material impact. No company benefits directly from this regulatory tightening, though contract testing laboratories (e.g., Eurofins Scientific, not publicly traded in the US) could see increased demand. 4) Market data analysis: $ABBV closed at $203.89 on 2026-04-29, up from $197.69 on 2026-04-28 (the Senate passage date). The +3.1% one-day move suggests the market has not priced in the bearish implications of this bill, likely because the House has not yet acted. However, the 30-day trend shows a -4.33% decline from ~$213 to $203.89, and the stock is trading well below its $244.81 52-week high. The 7-day change is +1.46%, reflecting some recovery from the April 24 low of $198.71. This bill adds a specific regulatory headwind that is currently underappreciated. 5) Timeline: The bill now moves to the House, where it will need to be introduced (no House companion has been publicly identified in the provided data) or the Senate bill must be taken up by a House committee. Given the unanimous consent passage in the Senate, the bill has high momentum. If the House passes it and the President signs it, the effective date would be 90-180 days after enactment, based on the bill's provisions requiring FDA response within 1 business day and manufacturer compliance. Passage by Q3 2026 is plausible.